Shares of AstraZeneca PLC (LON:AZN – Get Rating) have been assigned a consensus rating of “Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is £113.83 ($138.69).
A number of research analysts have weighed in on AZN shares. Barclays set a £125 ($152.29) price target on shares of AstraZeneca in a research report on Tuesday. The Goldman Sachs Group set a GBX 6,950 ($84.67) price target on shares of AstraZeneca in a research report on Thursday, November 10th. Jefferies Financial Group set a £108 ($131.58) price target on shares of AstraZeneca in a research report on Thursday, January 5th. UBS Group set a £101 ($123.05) target price on shares of AstraZeneca in a research report on Monday. Finally, Berenberg Bank reissued a “buy” rating and set a £118 ($143.76) target price on shares of AstraZeneca in a research report on Tuesday, November 22nd.
AstraZeneca Trading Up 0.6 %
Shares of AZN stock opened at £118.02 ($143.79) on Wednesday. The stock has a market cap of £182.88 billion and a price-to-earnings ratio of 11,240.00. The company has a quick ratio of 0.59, a current ratio of 0.81 and a debt-to-equity ratio of 88.97. AstraZeneca has a fifty-two week low of GBX 8,214 ($100.07) and a fifty-two week high of £118.86 ($144.81). The firm’s 50 day moving average price is £111.46 and its two-hundred day moving average price is £107.46.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Is Salesforce’s New Rally The Beginning Of A Big Uptrend?
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
- Skechers Not Nike Is The Sneaker Stock to Own for 2023
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.